



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	Rilpivirine (TMC278)
Catalog Number:	12147
Lot Number:	110177
Release Category:	E
Provided:	20 mg
Chemical Name:	4-[[4-[[4-(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzotrile
Empirical Formula:	C ₂₂ H ₁₈ N ₆
HPLC Purity:	99.6% (by HPLC)
Molecular Weight:	366.43
CAS Num:	500287-72-9
Solubility:	Rilpivirine is soluble in water at < 0.1gm/L. It is soluble in DMSO.
Mechanical Action:	Rilpivirine, also known as Edurant or TMC278 is a HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a second generation NNRTI with higher potency, longer half-life and reduced side-effect profile as compared with older NNRTIs, such as Efavirenz. WARNING: Harmful if swallowed. May be harmful by inhalation.
Special Characteristics:	All recipients must complete the TMC278 Addendum prior to receipt of this reagent. TMC278 Addendum

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Recommended Storage:

Room temperature (25°C).

Contributor:

Tibotec Pharmaceuticals, Inc.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Rilpivirine (Cat # 12147) from Tibotec Pharmaceuticals, Inc."

This compound is restricted for "research purposes only" and is limited to 40 mg per requester per year.

Requesters from commercial institutions should be directed to Richard Hoetelmans, PhD, Global Head Clinical Pharmacology, Infectious Diseases, Tibotec, Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium, tel (+) 32 14 641 478, Email: rhoetelm@tibbe.ini.com.

Recipient agrees that the reagent (Rilpivirine) use is permitted only as a standard for in vitro and/or studies in animals for inhibition of HIV replication.

Last Updated

February 24, 2014

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.